Anzeige
Mehr »
Login
Montag, 31.03.2025 Börsentäglich über 12.000 News von 696 internationalen Medien
Ad-hoc-Meldung: Gleich zu Wochenbeginn prozentual dreistellig? Der frühe Vogel…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40UHG | ISIN: US7389201077 | Ticker-Symbol:
NASDAQ
28.03.25
20:39 Uhr
0,640 US-Dollar
-0,022
-3,25 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
ASPIRE BIOPHARMA HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
ASPIRE BIOPHARMA HOLDINGS INC 5-Tage-Chart

Aktuelle News zur ASPIRE BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
20.03.Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin178Subsequent phase involves completion of chemistry, manufacturing, and controls (CMC) testing for data to support FDA submissionCompany expects to commence bioavailability study in April 2025Aspire intends...
► Artikel lesen
13.03.Aspire Biopharma treibt Patentanmeldungen für Arzneimittelverabreichungstechnologie voran5
13.03.Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform196HUMACAO, PUERTO RICO AND NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug...
► Artikel lesen
11.03.SCD Media, LLC: An Interview with the CEO: How Aspire Biopharma is Disrupting a $100 Billion Market with Sublingual Innovation158New York, New York--(Newsfile Corp. - March 11, 2025) - Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP) ("Aspire" or the "Company") is revolutionizing drug delivery through its proprietary sublingual...
► Artikel lesen
03.03.Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement193New product expected to set a new standard for potency and performance in the estimated $20 billon pre-workout marketDesert Stream Inc., a well-established nutritional and supplement manufacturer of...
► Artikel lesen
25.02.Aspire Biopharma advances to phase 1 clinical trial for aspirin product2
ASPIRE BIOPHARMA Aktie jetzt für 0€ handeln
25.02.Aspire Biopharma startet Phase-1-Studie für Aspirin-Produkt3
25.02.Aspire Biopharma, Inc.: Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin343Initial feasibility study of its soluble, Ph neutral, fast acting granular or powder drug delivery system is completeTest results support the next development step with Phase 1clinical trial expected...
► Artikel lesen
21.02.Aspire Biopharma, Inc.: Aspire Biopharma Holdings, Inc. Announces the Execution of Securities Purchase Agreement490NEW YORK CITY, NY / ACCESS Newswire / February 20, 2025 / Aspire Biopharma, Inc. ("Aspire" or the "Company"), a developer of a multi-faceted patent-protected disruptive drug delivery mechanism technology...
► Artikel lesen
20.02.Aspire Biopharma Holdings, Inc. - 8-K, Current Report-
20.02.Aspire Biopharma announces public listing on Nasdaq2
19.02.Aspire Biopharma begins trading on Nasdaq post-merger3
19.02.Aspire Biopharma, Inc.: Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq397NEW YORK CITY, NY / ACCESS Newswire / February 19, 2025 / Aspire Biopharma, Inc. ("Aspire" or the "Company"), a developer of a multi-faceted patent-protected disruptive drug delivery mechanism technology...
► Artikel lesen
08.01.Aspire BioPharma Inc. - S-4/A, Registration of securities, business combinations-
23.12.24Aspire BioPharma Inc. - S-4/A, Registration of securities, business combinations-
10.12.24Aspire BioPharma Inc. - S-4/A, Registration of securities, business combinations-
15.11.24Aspire BioPharma Inc. - S-4/A, Registration of securities, business combinations-
24.10.24Aspire BioPharma Inc. - S-4/A, Registration of securities, business combinations3
03.09.24Aspire Biopharma, Inc., and PowerUp Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-listed Biopharmaceutical Company Driving Breakthrough Innovations in FDA Approved Drugs, Nutraceuticals and Supplements196Highlights Transaction Valuation: The transaction values Aspire Biopharma, Inc. at a pre-money equity value of approximately $316 million.Industry-Leading Platform: Aspire is focused on developing...
► Artikel lesen
31.07.24Aspire Biopharma, Inc. Signs Letter of Intent to Create a Publicly Listed, Drug Delivery Company Through a Business Combination with PowerUp Acquisition Corp.94Humacao, PR and New York, NY, July 31, 2024 (GLOBE NEWSWIRE) -- Aspire Biopharma, Inc. ("Aspire" or the "Company"), a developer of a multi-faceted patent protected disruptive drug delivery mechanism...
► Artikel lesen
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1